Developer docs
API playgroundTry for free, no card

Search company profiles

Orbital Therapeutics

Full company profile

uuid00003ke

Namestring
Orbital Therapeutics
Legal namestring
Orbital Therapeutics, Inc.
Websiteurl
orbitaltx.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Orbital Therapeutics was a privately-held, pre-revenue biotechnology company founded in September 2022 in Cambridge, Massachusetts, that built an integrated RNA medicines platform to develop next-generation RNA-based therapeutics for human disease. The company's core technical approach combined established and emerging RNA technologies (excluding RNAi) with non-viral delivery mechanisms, centered on circular RNA delivered via lipid nanoparticles (LNPs) to enable in vivo cell reprogramming. Its lead preclinical candidate, OTX-201, was an in vivo CD19 CAR-T cell therapy designed to deplete autoreactive B cells and reset the immune system in B cell-driven autoimmune diseases such as rheumatoid arthritis and lupus, aiming to eliminate the costly and complex lab-based manufacturing burden of traditional ex vivo CAR-T therapies.

The business model was that of a preclinical platform biotech: the company did not commercialize products and derived no product revenue, instead pursuing strategic partnerships, licensing, and ultimately acquisition by a major pharmaceutical company. Orbital launched in September 2022 with a founding strategic partnership and license/research collaboration with Beam Therapeutics, gaining shared access to RNA and non-viral delivery technologies spanning vaccines, immunomodulation, protein replacement, and regenerative medicine. It raised a $270 million Series A financing in April 2023 led by ARCH Venture Partners, with participation from Andreessen Horowitz, EXOR, Redmile, and other top-tier biotech investors, and operated with a headcount of 51-100 employees. In October 2025, Bristol Myers Squibb acquired Orbital for $1.5 billion in cash to absorb OTX-201, the RNA platform, and next-generation in vivo CAR-T candidates into BMS's cell therapy portfolio, after which Orbital ceased operating as an independent entity and became a wholly-owned subsidiary of BMS.

Short descriptiontext

Orbital Therapeutics was a Cambridge, MA-based preclinical biotech founded in 2022 that built a proprietary RNA medicines platform combining circular RNA and lipid nanoparticle delivery to develop in vivo CD19 CAR-T therapies for B cell-driven autoimmune diseases, acquired by Bristol Myers Squibb for $1.5 billion in October 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA therapeutics, in vivo CAR-T therapy, circular RNA platform, autoimmune disease therapy, lipid nanoparticle delivery
Industry4 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
RNA Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pipeline Development and Licensing
TypeLicensing Royalties
Description

Pre-revenue biotech developing RNA-based therapeutics with focus on in vivo CAR-T cell therapies for autoimmune diseases. Revenue derived through strategic partnerships, licensing deals, and ultimately through acquisition by major pharma.

biospace.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Orbital Therapeutics develops RNA-based medicines, with its lead candidate OTX-201 being a circular RNA in vivo CAR-T therapy intended for B cell-driven autoimmune diseases. The platform combines circRNA construct engineering with lipid nanoparticle delivery to enable in vivo generation of CAR-T cells, eliminating the need for ex vivo cell manufacturing. Additional programs target regenerative medicine and oncology through diverse RNA modalities.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Orbital Therapeutics was a single-product biotech company with a proprietary RNA platform. The company's core asset was OTX-201, an in vivo CAR T-cell therapy for autoimmune diseases, combined with its circular RNA delivery platform that enabled reprogramming of cells inside the body. The company was acquired by Bristol Myers Squibb in October 2025 for $1.5 billion.

Product and service1 record
1OTX-201
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Bristol Myers Squibb
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Bristol Myers Squibb acquired Orbital Therapeutics for $1.5 billion in cash in October 2025. The acquisition provided BMS access to Orbital's lead preclinical candidate OTX-201 (circular RNA therapy for B cell-driven autoimmune diseases), its proprietary RNA platform, and next-generation in vivo CAR-T therapy candidates. The deal enhanced BMS's cell therapy research platform and positioned the company to develop potentially more accessible treatments compared to traditional ex vivo CAR-T therapies.

biospace.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-07
Description

Orbital Therapeutics entered into a strategic partnership with Beam Therapeutics at launch in September 2022. The license and research collaboration provided shared access to RNA and non-viral delivery technologies for specific applications including vaccines and therapeutic proteins. The partnership focused on leveraging innovative RNA technologies and delivery mechanisms to develop RNA medicines for treating human diseases in areas of vaccines, immunomodulation, protein replacement, and regenerative medicine.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Beam Therapeutics was Orbital's launch partner and a leading base-editing biotech. Both companies work with RNA and non-viral delivery technologies, and Beam monetized its Orbital stake for $255.1M after the BMS acquisition, making it a directly comparable peer in RNA-based therapeutic development.

TypeDirect peer
Description

Intellia is advancing in vivo CRISPR-based gene editing and cell therapy using LNP delivery for both autoimmune and oncological indications. It is a direct peer to Orbital in the in vivo cell engineering space using non-viral delivery.

TypeDirect peer
Description

Caribou develops allogeneic CAR-T cell therapies including allogeneic CAR-T candidates for autoimmune disease. It competes with Orbital in next-generation CAR-T approaches, though focused on ex vivo allogeneic rather than in vivo delivery.

TypeBroad incumbent
Description

Moderna is the leading mRNA therapeutics company with extensive LNP delivery expertise and a broad pipeline including immuno-oncology and rare disease applications. As an established RNA therapeutics incumbent, it overlaps with Orbital's core technology platform.

TypeBroad incumbent
Description

BioNTech is a major mRNA therapeutics company with programs in cancer immunotherapy and infectious disease vaccines. Its work on RNA-based cell therapies and LNP delivery platforms makes it a broad incumbent comparable to Orbital's RNA medicines approach.

TypeDirect peer
Description

Arcturus develops RNA-based therapeutics using its STARR and LUNAR delivery platforms, including self-amplifying RNA and conventional mRNA. It is a direct peer in the RNA therapeutics space with non-viral delivery technology comparable to Orbital's circular RNA + LNP platform.

TypeBroad incumbent
Description

Alnylam is the leading RNAi therapeutics company with established GalNAc and LNP-based delivery platforms. While focused on RNAi rather than mRNA/circular RNA, it is a broad incumbent in the RNA therapeutics space and a relevant comparable.

TypeDirect peer
Description

CRISPR Therapeutics is developing ex vivo and in vivo gene-edited cell therapies, including CAR-T candidates for autoimmune disease. Its work on in vivo gene editing and cell therapy delivery overlaps directly with Orbital's in vivo CAR-T platform.

9Laronde
TypeDirect peer
Description

Laronde is developing endless RNA (eRNA), a circular RNA therapeutic platform. As a direct circular RNA therapeutics competitor with non-viral delivery, it is one of the closest technology peers to Orbital's circular RNA platform.

TypeDirect peer
Description

Editas Medicine develops in vivo and ex vivo gene-editing therapies including cell therapy approaches for cancer and autoimmune disease. It is a comparable peer in the in vivo cell engineering and gene editing therapeutic space.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Orbital Therapeutics

RNA Therapeuticsorbitaltx.com

Orbital Therapeutics was a Cambridge, MA-based preclinical biotech founded in 2022 that built a proprietary RNA medicines platform combining circular RNA and lipid nanoparticle delivery to develop in vivo CD19 CAR-T therapies for B cell-driven autoimmune diseases, acquired by Bristol Myers Squibb for $1.5 billion in October 2025.

What Orbital Therapeutics does

Orbital Therapeutics was a privately-held, pre-revenue biotechnology company founded in September 2022 in Cambridge, Massachusetts, that built an integrated RNA medicines platform to develop next-generation RNA-based therapeutics for human disease. The company's core technical approach combined established and emerging RNA technologies (excluding RNAi) with non-viral delivery mechanisms, centered on circular RNA delivered via lipid nanoparticles (LNPs) to enable in vivo cell reprogramming. Its lead preclinical candidate, OTX-201, was an in vivo CD19 CAR-T cell therapy designed to deplete autoreactive B cells and reset the immune system in B cell-driven autoimmune diseases such as rheumatoid arthritis and lupus, aiming to eliminate the costly and complex lab-based manufacturing burden of traditional ex vivo CAR-T therapies.

The business model was that of a preclinical platform biotech: the company did not commercialize products and derived no product revenue, instead pursuing strategic partnerships, licensing, and ultimately acquisition by a major pharmaceutical company. Orbital launched in September 2022 with a founding strategic partnership and license/research collaboration with Beam Therapeutics, gaining shared access to RNA and non-viral delivery technologies spanning vaccines, immunomodulation, protein replacement, and regenerative medicine. It raised a $270 million Series A financing in April 2023 led by ARCH Venture Partners, with participation from Andreessen Horowitz, EXOR, Redmile, and other top-tier biotech investors, and operated with a headcount of 51-100 employees. In October 2025, Bristol Myers Squibb acquired Orbital for $1.5 billion in cash to absorb OTX-201, the RNA platform, and next-generation in vivo CAR-T candidates into BMS's cell therapy portfolio, after which Orbital ceased operating as an independent entity and became a wholly-owned subsidiary of BMS.

Orbital Therapeutics firmographics

Firmographics
Name
Orbital Therapeutics
Legal name
Orbital Therapeutics, Inc.
Website
https://orbitaltx.com
Company type
Private
Founded year
2022
Operating status
Acquired
Headcount range
1–10 employees
Short description
Orbital Therapeutics was a Cambridge, MA-based preclinical biotech founded in 2022 that built a proprietary RNA medicines platform combining circular RNA and lipid nanoparticle delivery to develop in vivo CD19 CAR-T therapies for B cell-driven autoimmune diseases, acquired by Bristol Myers Squibb for $1.5 billion in October 2025.
Ownership category
akta.pro rank

Orbital Therapeutics industry classification

Industry
Product category
RNA Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • RNA therapeutics
  • In vivo CAR-T therapy
  • Circular RNA platform
  • Autoimmune disease therapy
  • Lipid nanoparticle delivery

Where Orbital Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Orbital Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Pipeline Development and Licensing: Pre-revenue biotech developing RNA-based therapeutics with focus on in vivo CAR-T cell therapies for autoimmune diseases. Revenue derived through strategic partnerships, licensing deals, and ultimately through acquisition by major pharma.

Go-to-market motion1 record

Marketing channels1 record

Orbital Therapeutics product offering

Product offering

Core offering

Orbital Therapeutics develops RNA-based medicines, with its lead candidate OTX-201 being a circular RNA in vivo CAR-T therapy intended for B cell-driven autoimmune diseases. The platform combines circRNA construct engineering with lipid nanoparticle delivery to enable in vivo generation of CAR-T cells, eliminating the need for ex vivo cell manufacturing. Additional programs target regenerative medicine and oncology through diverse RNA modalities.

Product overview

Orbital Therapeutics was a single-product biotech company with a proprietary RNA platform. The company's core asset was OTX-201, an in vivo CAR T-cell therapy for autoimmune diseases, combined with its circular RNA delivery platform that enabled reprogramming of cells inside the body. The company was acquired by Bristol Myers Squibb in October 2025 for $1.5 billion.

Differentiator

Problem solved

Functional benefit

Products and services

  • OTX-201

Companies that use Orbital Therapeutics

Customer profile

Segments2 records

Ideal customer profiles1 record

Orbital Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Orbital Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Bristol Myers SquibbcoreStrategic or Co-development Partner · 1 October 2025Bristol Myers Squibb acquired Orbital Therapeutics for $1.5 billion in cash in October 2025. The acquisition provided BMS access to Orbital's lead preclinical candidate OTX-201 (circular RNA therapy for B cell-driven autoimmune diseases), its proprietary RNA platform, and next-generation in vivo CAR-T therapy candidates. The deal enhanced BMS's cell therapy research platform and positioned the company to develop potentially more accessible treatments compared to traditional ex vivo CAR-T therapies.
  • Beam TherapeuticscoreStrategic or Co-development Partner · 7 September 2022Orbital Therapeutics entered into a strategic partnership with Beam Therapeutics at launch in September 2022. The license and research collaboration provided shared access to RNA and non-viral delivery technologies for specific applications including vaccines and therapeutic proteins. The partnership focused on leveraging innovative RNA technologies and delivery mechanisms to develop RNA medicines for treating human diseases in areas of vaccines, immunomodulation, protein replacement, and regenerative medicine.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Orbital Therapeutics competitors and assessment

Company assessment

Direct peers

  • Beam Therapeutics: Beam Therapeutics was Orbital's launch partner and a leading base-editing biotech. Both companies work with RNA and non-viral delivery technologies, and Beam monetized its Orbital stake for $255.1M after the BMS acquisition, making it a directly comparable peer in RNA-based therapeutic development.
  • Intellia Therapeutics: Intellia is advancing in vivo CRISPR-based gene editing and cell therapy using LNP delivery for both autoimmune and oncological indications. It is a direct peer to Orbital in the in vivo cell engineering space using non-viral delivery.
  • Caribou Biosciences: Caribou develops allogeneic CAR-T cell therapies including allogeneic CAR-T candidates for autoimmune disease. It competes with Orbital in next-generation CAR-T approaches, though focused on ex vivo allogeneic rather than in vivo delivery.
  • Arcturus Therapeutics: Arcturus develops RNA-based therapeutics using its STARR and LUNAR delivery platforms, including self-amplifying RNA and conventional mRNA. It is a direct peer in the RNA therapeutics space with non-viral delivery technology comparable to Orbital's circular RNA + LNP platform.
  • CRISPR Therapeutics: CRISPR Therapeutics is developing ex vivo and in vivo gene-edited cell therapies, including CAR-T candidates for autoimmune disease. Its work on in vivo gene editing and cell therapy delivery overlaps directly with Orbital's in vivo CAR-T platform.
  • Laronde: Laronde is developing endless RNA (eRNA), a circular RNA therapeutic platform. As a direct circular RNA therapeutics competitor with non-viral delivery, it is one of the closest technology peers to Orbital's circular RNA platform.
  • Editas Medicine: Editas Medicine develops in vivo and ex vivo gene-editing therapies including cell therapy approaches for cancer and autoimmune disease. It is a comparable peer in the in vivo cell engineering and gene editing therapeutic space.

Broad incumbents

  • Moderna: Moderna is the leading mRNA therapeutics company with extensive LNP delivery expertise and a broad pipeline including immuno-oncology and rare disease applications. As an established RNA therapeutics incumbent, it overlaps with Orbital's core technology platform.
  • BioNTech: BioNTech is a major mRNA therapeutics company with programs in cancer immunotherapy and infectious disease vaccines. Its work on RNA-based cell therapies and LNP delivery platforms makes it a broad incumbent comparable to Orbital's RNA medicines approach.
  • Alnylam Pharmaceuticals: Alnylam is the leading RNAi therapeutics company with established GalNAc and LNP-based delivery platforms. While focused on RNAi rather than mRNA/circular RNA, it is a broad incumbent in the RNA therapeutics space and a relevant comparable.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

Orbital Therapeutics social profiles

Digital presence

Orbital Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Orbital Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

Orbital Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Orbital Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orbital Therapeutics

What does Orbital Therapeutics do?

Orbital Therapeutics develops RNA-based medicines, with its lead candidate OTX-201 being a circular RNA in vivo CAR-T therapy intended for B cell-driven autoimmune diseases. The platform combines circRNA construct engineering with lipid nanoparticle delivery to enable in vivo generation of CAR-T cells, eliminating the need for ex vivo cell manufacturing. Additional programs target regenerative medicine and oncology through diverse RNA modalities.

Is Orbital Therapeutics a public or private company?

Orbital Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Orbital Therapeutics founded?

Orbital Therapeutics was founded in 2022. It employs 1 to 10 people.

Where is Orbital Therapeutics based?

Orbital Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Orbital Therapeutics make money?

One revenue line is on record: pipeline Development and Licensing.

Who are Orbital Therapeutics's main competitors?

Direct peers on record are Beam Therapeutics, Intellia Therapeutics, Caribou Biosciences, Arcturus Therapeutics, CRISPR Therapeutics, Laronde and Editas Medicine. Broad incumbents are Moderna, BioNTech and Alnylam Pharmaceuticals.

Does Orbital Therapeutics have an API?

No public API is recorded for Orbital Therapeutics.

What industry is Orbital Therapeutics in?

Orbital Therapeutics's product category is RNA Therapeutics. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Nate빅파마 베팅 이어지는 인비보 CAR-T…암 넘어 자가면역질환으로 : 네이트 뉴스Bristol Myers Squibb will start Phase 1 trials of its in vivo CAR-T candidate BMS-986553 on 30, targeting five autoimmune diseases with 60 patients. The company acquired the candidate from Orbital Therapeutics in October. Technical hurdles and domestic investment gaps remain.Naver빅파마 베팅 이어지는 인비보 CAR-T…암 넘어 자가면역질환으로Bristol Myers Squibb will start Phase 1 trials of its in vivo CAR-T candidate BMS-986553 for five autoimmune diseases, including lupus and rheumatoid arthritis. The trial involves 60 patients, and the company acquired the candidate from Orbital Therapeutics. Global pharma firms are racing to secure in vivo CAR-T technology, with domestic investment growth lagging behind the US and UK.Phirda超 30 亿美元!2026 年上半年 CAR-T 销售额出炉In H1 2026, five CAR-T drugs generated over $3 billion, with Carvykti leading at $1.254 billion. The market is shifting toward autoimmunity and in vivo CAR-T, with major players acquiring assets. Competition will focus on manufacturing capacity and next-generation platforms.European BiotechnologyCan Sanofi buy its way into in vivo CAR-T?Sanofi published preclinical data showing its in vivo CAR-T platform can deliver mRNA-encoded CARs to CD8+ T cells, generating functional CAR-T cells that inhibit tumor growth. The platform combines mRNA payloads, lipid nanoparticles, and targeted guidance from acquired companies, though CAR expression remains transient. The results are confined to hematological models, with broader applications pending.Labiotech.euEight in vivo CAR T biotechs to follow closelyEight in vivo CAR-T biotechs are profiled, including Umoja Biopharma, Vyriad, CPTx, Legend, Strand, Alaya.bio, AAVivo, and Create Medicines. Their lead candidates target CD19, BCMA, or other antigens, with some in clinical trials. Big pharma is acquiring these companies for billions.MarketScreenerValerio Therapeutics Appoints New Chief Executive OfficerValerio Therapeutics appointed Gilles Besin as its new CEO, effective July 1. The biotechnology firm's leadership change was announced on June 17, 2026.The Motley FoolLooking to Buy Bristol Myers Squibb Stock on the Dip? Read This First.Bristol Myers Squibb shares rebounded after a 11% drop, but the stock faces a patent cliff with Eliquis and Opdivo losing exclusivity in 2028. The company's legacy drugs still account for 46% of revenue, and acquisitions carry integration risks. A 4.2% dividend yield may attract income investors despite the risks.Labiotech.euIn vivo CAR-T gains momentum as big pharma bets billionsBig pharma is shifting toward in vivo CAR-T therapies, with Lilly planning a $7B acquisition of Kelonia Therapeutics. Other deals include AstraZeneca's $1B purchase of EsoBiotec and Gilead's $350M buy of Interius BioTherapeutics. The shift aims to overcome manufacturing and cost barriers of ex vivo CAR-T.The Motley Fool3 Healthcare Stocks That Pay You a Dividend While You Wait for a RecoveryMedtronic, Sanofi, and Bristol Myers Squibb pay dividends while their stocks have declined over recent periods. Medtronic's dividend yield is 3.3% with 48 consecutive increases, Sanofi's is 5.71%, and Bristol's is 4.2%. All three face revenue or patent concerns as investors await recovery.The Motley FoolWhich Dividend Pharma Stock Should a Value Investor Choose Today?Bristol Myers Squibb is being highlighted as a potential value stock for dividend investors, with a forward P/E ratio of 9.5, a 4.2% dividend yield, and consistent annual revenue of approximately $48 billion. The analysis acknowledges concerns including declining legacy portfolio revenue and over $47 billion in debt, but points to growing revenue from its growth portfolio and a potential $1.5 billion acquisition of Orbital Therapeutics in the RNA therapeutics space as pathways to address upcoming patent cliffs.